Teva Pharmaceutical Industries Limited (TEVA) Cut to “Underperform” at Credit Suisse Group

Credit Suisse Group cut shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) from a neutral rating to an underperform rating in a research report sent to investors on Wednesday, MarketBeat reports. They currently have $13.00 price target on the stock, down from their prior price target of $25.00.

Other equities analysts have also recently issued research reports about the company. Vetr raised Teva Pharmaceutical Industries Limited from a hold rating to a buy rating and set a $33.12 price target on the stock in a research note on Tuesday, May 2nd. Citigroup Inc. dropped their price target on Teva Pharmaceutical Industries Limited from $47.00 to $42.00 and set a buy rating on the stock in a research note on Tuesday, April 25th. Deutsche Bank AG dropped their price target on Teva Pharmaceutical Industries Limited from $45.00 to $43.00 and set a buy rating on the stock in a research note on Friday, May 12th. Oppenheimer Holdings, Inc. reissued a buy rating on shares of Teva Pharmaceutical Industries Limited in a research note on Wednesday, May 31st. Finally, Mizuho raised Teva Pharmaceutical Industries Limited from a neutral rating to a buy rating and lifted their price target for the stock from $25.00 to $30.00 in a research note on Thursday, June 15th. Four research analysts have rated the stock with a sell rating, twenty have assigned a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. Teva Pharmaceutical Industries Limited has an average rating of Hold and an average target price of $35.06.

Teva Pharmaceutical Industries Limited (NYSE TEVA) opened at 16.21 on Wednesday. Teva Pharmaceutical Industries Limited has a 52 week low of $15.85 and a 52 week high of $52.66. The firm’s 50-day moving average is $25.37 and its 200-day moving average is $30.35. The stock’s market capitalization is $16.47 billion.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last issued its quarterly earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.06 by $0.07. The company had revenue of $5.69 billion during the quarter, compared to analysts’ expectations of $5.72 billion. Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. The company’s revenue for the quarter was up 12.9% compared to the same quarter last year. During the same period in the prior year, the business posted $1.25 EPS. On average, equities research analysts predict that Teva Pharmaceutical Industries Limited will post $4.32 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “[[title]]” was first published by [[site]] and is the property of of [[site]]. If you are accessing this article on another domain, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The correct version of this article can be read at [[permalink]].

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 14th. Investors of record on Tuesday, August 29th will be issued a $0.085 dividend. The ex-dividend date is Friday, August 25th. This represents a $0.34 annualized dividend and a yield of 2.10%. Teva Pharmaceutical Industries Limited’s dividend payout ratio (DPR) is currently -14.22%.

A number of large investors have recently bought and sold shares of TEVA. Court Place Advisors LLC raised its stake in Teva Pharmaceutical Industries Limited by 10.3% in the first quarter. Court Place Advisors LLC now owns 9,332 shares of the company’s stock valued at $299,000 after buying an additional 875 shares during the period. ST Germain D J Co. Inc. raised its stake in Teva Pharmaceutical Industries Limited by 0.4% in the first quarter. ST Germain D J Co. Inc. now owns 69,183 shares of the company’s stock valued at $2,220,000 after buying an additional 295 shares during the period. Janney Montgomery Scott LLC raised its stake in Teva Pharmaceutical Industries Limited by 18.7% in the first quarter. Janney Montgomery Scott LLC now owns 303,332 shares of the company’s stock valued at $9,734,000 after buying an additional 47,809 shares during the period. Physicians Financial Services Inc. raised its stake in Teva Pharmaceutical Industries Limited by 16.1% in the first quarter. Physicians Financial Services Inc. now owns 11,508 shares of the company’s stock valued at $369,000 after buying an additional 1,600 shares during the period. Finally, Stonebridge Capital Management Inc. raised its stake in Teva Pharmaceutical Industries Limited by 52.0% in the first quarter. Stonebridge Capital Management Inc. now owns 26,165 shares of the company’s stock valued at $840,000 after buying an additional 8,955 shares during the period. Hedge funds and other institutional investors own 56.04% of the company’s stock.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.